Fischer, Urs

Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis

Webb, A. J., Fischer, U., Mehta, Z., & Rothwell, P. M. (2010) · The Lancet

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 729

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 289

Neurological manifestations and implications of COVID-19 pandemic

Tsivgoulis, G., Palaiodimou, L., Katsanos, A. H., Caso, V., Köhrmann, M., Molina, C., Cordonnier, C., Fischer, U., Kelly, P., Sharma, V. K., et al. (2020) · Therapeutic Advances in Neurological Disorders

Long-Term Effects of COVID-19COVID-19 Clinical Research Studies

Cited by 145

Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis

Stefanou, M.-I., Palaiodimou, L., Theodorou, A., Safouris, A., Fischer, U., Kelly, P. J., Dawson, J., Katan, M., Katsanos, A. H., Lambadiari, V., et al. (2024) · Therapeutic Advances in Neurological Disorders

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement

Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC

Venous Thromboembolism Diagnosis and ManagementAtrial Fibrillation Management and Outcomes

Cited by 2